Status:
UNKNOWN
COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes
Lead Sponsor:
Wenwen Yin
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
At present, in order to cope with the global pandemic of the COVID-19 virus, governments have introduced corresponding measures, COVID-19 lockdown is one of the most important measures. However, lockd...
Detailed Description
We recruit patients with type 2 diabetes who need to be isolated due to the COVID-19 epidemic, Our study will include young and middle-aged obese patients. The lockdown period is 21 days. The patients...
Eligibility Criteria
Inclusion
- Physician diagnosis of Type 2 diabetes for more than 6 months
- 0%\<HbA1c\<10.0%
- Quarantine for 21 days due to COVID-19 outbreak related reasons
- age: 18 \~ 55 yrs
- BMI≥24
- Be able use smart phones and the Internet
Exclusion
- Insulin pump users
- For female subjects: pregnancy or lactation, or subject may become pregnant during the study
- Patient who underwent obesity surgery to the exclusion of a gastric band, loosened or removed for more than a year
- Patients diagnosed with COVID-19 infection
- Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects' ability to follow the tailored advice
Key Trial Info
Start Date :
January 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 5 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04723550
Start Date
January 5 2021
End Date
January 5 2022
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Xuzhou NO.1 Peoples Hospital
Xuzhou, Jiangsu, China, 221000